A novel rapamycin analog is highly selective for mTORC1 in vivo

Rapamycin, an inhibitor of mechanistic Target Of Rapamycin Complex 1 (mTORC1), extends lifespan and shows strong potential for the treatment of age-related diseases. However, rapamycin exerts metabolic and immunological side effects mediated by off-target inhibition of a second mTOR-containing compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Schreiber, Katherine H., Arriola Apelo, Sebastian I., Yu, Deyang, Brinkman, Jacqueline A., Velarde, Michael C., Syed, Faizan A., Liao, Chen-Yu, Baar, Emma L., Carbajal, Kathryn A., Sherman, Dawn S., Ortiz, Denise, Brunauer, Regina, Yang, Shany E., Tzannis, Stelios T., Kennedy, Brian K., Lamming, Dudley W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642166/
https://www.ncbi.nlm.nih.gov/pubmed/31324799
http://dx.doi.org/10.1038/s41467-019-11174-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642166/
https://www.ncbi.nlm.nih.gov/pubmed/31324799
http://dx.doi.org/10.1038/s41467-019-11174-0

Ejemplares similares